Evidence map›Paper›PMID 25491674›Full record

ArticleWorld journal of urology2015

Urinary cytokines in patients treated with intravesical mitomycin-C with and without hyperthermia.

Tom J H Arends, Johannes Falke, Rianne J M Lammers, Diederik M Somford, Jan C M Hendriks, Mirjam C A de Weijert, Harm C Arentsen, Antoine G van der Heijden, Egbert Oosterwijk, J Alfred Witjes

Abstract read
PubMed Publisher
In one paragraph

Article in World journal of urology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. DPPGInternational journal of nanomedicine · 2021
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Tom J H ArendsDepartment of Urology, Radboud University Medical Centre, Geert Grooteplein zuid 10, 6525 GA, Nijmegen, The Netherlands. Tom.arends@radboudumc.nl.
Johannes FalkeDepartment of Urology, Radboud University Medical Centre, Geert Grooteplein zuid 10, 6525 GA, Nijmegen, The Netherlands. josfalke@gmail.com.
Rianne J M LammersDepartment of Urology, Radboud University Medical Centre, Geert Grooteplein zuid 10, 6525 GA, Nijmegen, The Netherlands. Rianne_lammers@hotmail.com.
Diederik M SomfordCanisius Wilhelmina Ziekenhuis, Weg door Jonkerbos 100, 6532 SZ, Nijmegen, The Netherlands. r.somford@cwz.nl.
Jan C M HendriksBiostatistician, Department for Health Evidence, Radboud University Medical Centre, Geert Grooteplein zuid 10, 6525 GA, Nijmegen, The Netherlands. Jan.cm.hendriks@radboudumc.nl.
Mirjam C A de WeijertDepartment of Urology, Radboud University Medical Centre, Geert Grooteplein zuid 10, 6525 GA, Nijmegen, The Netherlands. Mirjam.deweijert@radboudumc.nl.
Harm C ArentsenDepartment of Urology, Radboud University Medical Centre, Geert Grooteplein zuid 10, 6525 GA, Nijmegen, The Netherlands. Harm.arentsen@radboudumc.nl.
Antoine G van der HeijdenDepartment of Urology, Radboud University Medical Centre, Geert Grooteplein zuid 10, 6525 GA, Nijmegen, The Netherlands. toine.vanderheijden@radboudumc.nl.
Egbert OosterwijkDepartment of Urology, Radboud University Medical Centre, Geert Grooteplein zuid 10, 6525 GA, Nijmegen, The Netherlands. Egbert.oosterwijk@radboudumc.nl.
J Alfred WitjesDepartment of Urology, Radboud University Medical Centre, Geert Grooteplein zuid 10, 6525 GA, Nijmegen, The Netherlands. fred.witjes@radboudumc.nl.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo explore whether urinary cytokine and chemokine (CK) levels differed between cold mitomycin-C (cold-MMC)-treated patients and chemohyperthermia (C-HT)-treated patients, to shed light on the possible molecular mechanisms that might explain the superior outcome of C-HT. Furthermore, CK-differences were explored between C-HT responders and C-HT non-responders.

methodsTwelve NMIBC patients were included. Nine received six-weekly C-HT, and three received four-weekly cold-MMC instillations. Urine was collected on 8-12 time points before and after every treatment. MDC, IL-2, IL-6, IL-8, IP-10, MCP-1 and RANTES were determined by Luminex(®)-analysis.

resultsElevated urinary CK levels were observed in both groups after treatment. In general, CK-peaks were lower in the cold-MMC group in comparison with levels in the C-HT group. Significant higher MCP-1 and IL-6 levels were observed in C-HT-treated patients. Additionally, significant cumulative effects were observed for IP-10 and IL-2. However, IP-10 and IL-2 levels did not significantly differ between treatments. MDC levels after the first week of treatment were significantly higher in the C-HT responders compared with the non-responders.

conclusionMMC treatment leads to elevated urinary CK levels with significantly higher MCP-1 and IL-6 levels in C-HT-treated patients. Increased MDC levels after the first C-HT instillation appear to be related to good clinical outcome and might be of additional value to personalize treatment. Studies involving more patients and longer follow-up are needed to substantiate this observation.

Indexed as

Administration, IntravesicalAgedAged, 80 and overAntibiotics, AntineoplasticBiomarkers, TumorCarcinoma, Transitional CellCytokinesDose-Response Relationship, DrugDrug Administration ScheduleFemaleHumansHyperthermia, InducedInstillation, DrugMaleMiddle AgedMitomycinAntibiotics, AntineoplasticBiomarkers, TumorCytokinesMitomycinBladder cancerBladder instillationChemotherapyCytokinesInduced hyperthermia

Identifiers

PMID25491674

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.